Compare VAL & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VAL | GRFS |
|---|---|---|
| Founded | 1975 | 1940 |
| Country | | |
| Employees | 5642 | 23800 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.5B |
| IPO Year | N/A | N/A |
| Metric | VAL | GRFS |
|---|---|---|
| Price | $92.73 | $9.49 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $54.80 | $10.15 |
| AVG Volume (30 Days) | ★ 2.4M | 422.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.47% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $5.47 |
| Revenue Next Year | N/A | $4.92 |
| P/E Ratio | ★ $16.22 | $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.15 | $6.19 |
| 52 Week High | $96.40 | $11.14 |
| Indicator | VAL | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 74.79 | 53.84 |
| Support Level | $57.78 | $9.07 |
| Resistance Level | $96.40 | $9.77 |
| Average True Range (ATR) | 5.09 | 0.23 |
| MACD | 2.71 | 0.02 |
| Stochastic Oscillator | 90.98 | 55.71 |
Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.